| |
著者: Ichiro Katayama, Yorihisa Kotobuki, Eiji Kiyohara, Hiroyuki Murota
雑誌名: Mod Rheumatol. 2010 Apr;20(2):123-9. doi: 10.1007/s10165-009-0257-y. Epub 2010 Jan 8.
Abstract/Text
Annular erythema has been recognized to be a specific, cutaneous manifestation associated with Sjögren's syndrome. Based on a search of the literature up to 2007, annular erythema with Sjögren's syndrome (AESS) preferentially occurs in Asian but not in Western populations. However, the precise clinical course and standard regimen for the management of AESS have remained obscure, primarily because of its rare occurrence in Western populations and the fact that most Asian cases are isolated reports. In this study, 28 cases of AESS from our department and 92 cases distilled from the literature were enrolled in a retrospective study to evaluate the clinical characteristics and most desirable management of this skin manifestation in Sjögren's syndrome. We found that 75% of all cases with AESS were positive for both anti-SSA and anti-SSB antibodies. Multiple therapeutic options are available to treat AESS, including oral steroids. Several anti-malaria drugs or tacrolimus ointment have also been reported to be effective against AESS. AESS is a distinct clinical entity, and a small dose of prednisolone (approx. 10 mg) is sufficient to control diseases activity, except in some cases with systemic manifestations, and this treatment has a more rapid clinical effect than topical steroids.
PMID 20054701 Mod Rheumatol. 2010 Apr;20(2):123-9. doi: 10.1007/s10165-009-0257-y. Epub 2010 Jan 8.
|
